Kyowa Hakko Kogyo to Introduce Self-Injectable Drug for Treating Parkinson's Disease from Britannia Pharmaceuticals.Tokyo, Japan, Feb 23, 2006 - (JCN JCN Japan Corporate News JCN Journal of Cognitive Neuroscience JCN Journal of Cardiovascular Nursing JCN Journal of Christian Nursing JCN Job Control Number JCN Journal of Child Neurology JCN joint communications network (US DoD) ) - Kyowa Hakko Kogyo announced on February 22 that it has concluded a licensing agreement with UK company Britannia Pharmaceuticals for a self-injectable formulation of apomorphine ap·o·mor·phine n. A poisonous, white, crystalline alkaloid derived from morphine and used medicinally to induce vomiting. apomorphine an alkaloid from morphine. . Under the agreement terms, Kyowa receives an exclusive right to develop and market the agent in Japan and some Asian countries. Accordingly, Kyowa will undertake a clinical development of the agent in Japan while making upfront and milestone payments to Britannia Pharmaceuticals. Apomorphin is a dopamine receptor Dopamine receptors are a class of metabotropic G protein-coupled receptors that are prominent in the vertebrate central nervous system (CNS). The neurotransmitter dopamine is the primary endogenous ligand for dopamine receptors. antagonist which is indicated for the treatment of advanced Parkinson's disease Parkinson's disease or Parkinsonism, degenerative brain disorder first described by the English surgeon James Parkinson in 1817. When there is no known cause, the disease usually appears after age 40 and is referred to as Parkinson's disease. . The agent is currently approved and marketed in major countries including the UK and the US. Copyright [c] 2006 Japan Corporate News Network. All rights reserved. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion